No abstract

Background: The surface antigen CD319 (SLAMF7) is a marker of normal and malignant plasma cells in plasma cell myeloma. In view of the potential therapeutic use of SLAMF7-targeting antibodies, such as elotuzumab, the detection of SLAMF7 expression levels on abnormal plasma cells might play an important role in the evaluation of therapy responses. Objective: This study aimed to evaluate role of CD319 marker in diagnosis and prognosis of plasma cell myeloma patients. Patients and Methods: The study was Cohort study conducted on newly diagnosed plasma cell myeloma patients in